Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CPI-613 + Cytarabine + Mitoxantrone|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CPI-613||CPI-613 is an inhibitor of pyruvate dehydrogenase (PDH) and alpha-ketogluterate (KGDH), resulting in blockade of mitochondrial respiration which may lead to apoptosis and death of cancer cells (PMID: 29437791, PMID: 28495639).|
|Cytarabine||Cytosar-U||Ara-C||Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (PMID: 32524309).|
|Mitoxantrone||Novantrone||CL 232315||Novantrone (Mitoxantrone) binds to and inhibits topoisomerase II, leading to DNA double strand breaks and decreased DNA repair (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute myeloid leukemia||not applicable||CPI-613 + Cytarabine + Mitoxantrone||Phase I||Actionable||In Phase I trial, the combination therapy, CPI-613 with Cytosar-U and Novantrone (Mitoxantrone), resulted in an overall response rate of 50% (31/62) in acute myeloid leukemia patients and a median survival of 6.7 months, and in patients over 60 years of age, the combined therapy led to a 47% (15/32) complete response rate and median survival of 6.9 months (PMID: 29437791).||29437791|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03504410||Phase III||Cytarabine + Mitoxantrone CPI-613 + Cytarabine + Mitoxantrone||Study Evaluating Efficacy and Safety of CPI-613 in Combination With HD Cytarabine and Mitoxantrone vs HD Cytarabine and Mitoxantrone in Older Patients With R/R AML||Recruiting|